Preparo e caracterização de nanopartículas de PLGA para liberação de acetato de dexametasona

• Ano de defesa: 2012
• Autor(a) principal: Izabella Maria Ferreira Campos
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; UFMG
• Palavras-chave em Português: Nanopartículas; Liberação controlada; Poli(ácido lático-co-ácido glicólico); Engenharia quimica
• Link de acesso: http://hdl.handle.net/1843/BUBD-9HDHDH

In this work, the preparation of PLGA nanoparticles containing dexamethasone acetate by nanoprecipitation technic, in the absence of organochlorine solvent, was investigated in order to develop controlled release devices. This system can be used in a broad range of applications, such as the treatment of ocular diseases. The human eye has an unique anatomical and physiological characteristics that hinder access to medicines for the treatment of diseases. Typically, these diseases are treated by systemic and topic administration routes of drugs. However, techniques have limitations on the availability and concentration of the active ingredient. The experimental strategy was divided in three stages. First, the most favorable condition for preparation of PLGA nanoparticles was defined by means of an experimental plan. After that, the incorporation of dexamethasone acetate and characterization of these nanoparticles was studied. The characterization techniques comprised size distribution, zeta potential, thermal analysis and scanning electron microscopy. In the third stage, the drug release profile was evaluated. Drug content was quantified by means of high performance liquid chromatography. The method was validated according to ANVISA rules. The results showed that it was possible to prepare nanometric particles by using this methodology. Dexamethasone containting PLGA particles showed an average size of (540 ± 4) nm with PDI (0.07 ± 0.01) and the zeta potential of -(2.5 ± 0.3) mV. Nanoparticles showed and espherical shape. The encapsulation efficiency was 48%. Tests in vitro showed that 25% of the drug was released in 48 hours.